NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood|2024Cited by 3
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, Zachary Lee et al.|Transplantation and Cellular Therapy|2025Cited by 3
NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphomaSairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Blood Advances|2025Cited by 1
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesKrina K. Patel, Miguel‐Angel Perales, Nina Shah et al.|Blood|2022Cited by 0
724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areataDavid Rosmarin, Charles Lynde, Neil S. Sadick et al.|British Journal of Dermatology|2024Cited by 0